- Exagamglogene autotemcel has shown promise in eliminating vaso-occlusive crises in patients with sickle cell disease for periods of 12 months or more in clinical trials
Monitoring for complications
- Monitoring for complications such as acute chest syndrome, stroke, and infection is essential. For acute chest syndrome, the NHLBI 2014 guidelines recommend administering intravenous cephalosporin, an oral macrolide antibiotic, and supplemental oxygen to maintain oxygen saturation above 95%
In conclusion, the management of vaso-occlusive crises in sickle cell disease requires a comprehensive approach that includes pain management, hydration, disease-modifying agents, novel therapies, and monitoring for complications.